DiaSys Corporation Announces Plans for Its Quick "Dipstick" Test for Multiple Myeloma Cancer; Reports Repeat Sales for Product in Europe.Business & Health/Medical Writers WATERBURY, Conn.--(BW HealthWire)--Feb. 12, 2001 DiaSys Corporation (AMEX AMEX See: American Stock Exchange : DYX DYX Dyslexia ) a designer, manufacturer and distributor of medical laboratory diagnostic instruments and consumables, announced today that its European subsidiary has developed an inexpensive rapid test for multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility ; an incurable, deadly bone disease that has very few symptoms in its early stages. The Company said that unlike current diagnostic methods, its test can be administered in 5-to-10 minutes at outpatient clinics, physician offices, or patient bedside, using freshly voided void·ed adj. Heraldry Having the central area cut out or left vacant, leaving an outline or narrow border: a voided lozenge. urine. The Company reported that its subsidiary has received repeat orders for the test in Europe, where the product is sold for research purposes. The Company then said that it is implementing plans to expand the technology to include other types of cancer, and to bring the technology to the United States, China and other world markets. DiaSys Corporation designs, develops, manufactures and distributes medical laboratory diagnostic instrumentation and consumables with applications in urinalysis, microbiology and cytology cytology (sītŏl`əjē), in biology, the study of the structure of all normal and abnormal components of cells and the changes, movements, and transformations of such components. . DiaSys is a registered trademark of DiaSys Corporation. The foregoing press release includes "forward looking statements" within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion